BioSpace News Archive

Biotech Beach

Dr. Ernst Von Schwarz: Study Shows Promising Benefit of Mesenchymal Stem Cell Injection in Critically Ill COVID-19 Patients

COVID-19 infections represent a life-threatening condition secondary to respiratory and multi-organ failure as a result of a systemic inflammatory response. Stem cell therapy might ameliorate the underlying effects likely secondary to anti-inflammatory properties.

September 27, 2021
·
2 min read
Business

Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy

Strategic senior hire strengthens Brii Bio’ leadership team and positions the Company for U.S. market access and commercialization

September 27, 2021
·
3 min read
Business

Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer’s Disease Under The Accelerated Approval Pathway

Eisai Co., Ltd. today announced that Eisai has initiated a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application (BLA) for lecanemab

September 27, 2021
·
13 min read
Policy

Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway

BioArctic AB’s partner Eisai announced that they have initiated a rolling submission to the U.S. Food and Drug Administration of a Biologics License Application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease.

September 27, 2021
·
5 min read
Business

D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China

D&D will receive an upfront payment of $4 million and is eligible to receive additional undisclosed milestone payments upon achievement of certain development and commercial milestones

September 27, 2021
·
3 min read
Biotech Beach

Aurora Spine Corporation Announces Participation at the North American Spine Society Annual Meeting

Aurora Spine Corporation today announced it would be participating at the 2021 North American Spine Society (“NASS”) Annual Meeting, September 29-October 2, 2021 at the Boston Convention Center in Boston, Massachusetts at Booth #1925.

September 27, 2021
·
3 min read
Drug Development

ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors

ADC Therapeutics SA today announced the first patient has been dosed in the Phase 1 clinical trial evaluating ADCT-901, targeting kidney associated antigen 1 (KAAG1), in patients with selected advanced solid tumors with high unmet medical needs.

September 27, 2021
·
3 min read
Business

CyanVac and Blue Lake Biotechnology Announce First Participant Dosed in a Phase 1 Clinical Trial to Evaluate its CVXGA1 Intranasal COVID-19 Vaccine

CyanVac LLC and its subsidiary, Blue Lake Biotechnology, Inc. today announced the enrollment of the first participant in a Phase 1 clinical trial of their CVXGA1 intranasal COVID-19 vaccine in Rochester, NY.

September 27, 2021
·
5 min read
Genetown

Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference

Intellia Therapeutics, Inc. will present at Chardan’s 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 10:30 a.m. ET.

September 27, 2021
·
1 min read
Lone Star Bio

Plus Therapeutics to Present at the Benzinga Healthcare Small Cap Conference

Plus Therapeutics, Inc. today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a Company overview during the Benzinga Healthcare Small Cap Conference on Thursday, Septemeber 30, 2021 at 4:20 p.m. ET.

September 27, 2021
·
4 min read